Compare ERO & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ERO | HRMY |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.2B |
| IPO Year | 2021 | 2020 |
| Metric | ERO | HRMY |
|---|---|---|
| Price | $25.68 | $36.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $36.50 | ★ $44.11 |
| AVG Volume (30 Days) | ★ 1.2M | 768.4K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | N/A | ★ 0.55 |
| Revenue | N/A | ★ $868,453,000.00 |
| Revenue This Year | $51.94 | $19.75 |
| Revenue Next Year | $2.43 | $12.88 |
| P/E Ratio | ★ $22.61 | $69.47 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $12.79 | $25.52 |
| 52 Week High | $39.80 | $40.87 |
| Indicator | ERO | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 44.84 | 58.67 |
| Support Level | $25.42 | $35.05 |
| Resistance Level | $26.77 | $39.12 |
| Average True Range (ATR) | 1.24 | 1.23 |
| MACD | -0.23 | 0.13 |
| Stochastic Oscillator | 36.03 | 60.10 |
Ero Copper Corp is a high-margin, high-growth copper producer with operations in Brazil. Its primary asset is its 99.6% ownership interest in Mineracao Caraiba S.A., held indirectly through its wholly-owned subsidiary. The company also owns a 97.6% ownership interest in NX Gold S.A. indirectly through its wholly-owned subsidiary. Its reporting segments include its three operating mines in Brazil, the Caraiba Operations, the Tucuma Operation, and the Xavantina Operations, and its corporate head office in Canada.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.